US5833651A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic intraluminal stents
Assignee: Medtronic Inc
•
Filing: 1996-11-08
•
Granted: 1998-11-10
•
Expires: 2016-11-08
Abstract
Abstract This invention relates to an intraluminal stent having a lumen-wall contacting surface and a lumen-exposed surface wherein the stent comprises a first polymer composition comprising fibrin and wherein the stent is suitable to deliver virus to the wall of a lumen of the body. The invention also relates to methods for making the stent and to methods for delivering nucleic acid to cells accessible from a wall of a body lumen.
Inventors
- 👤 Maura G. Donovan
- 👤 Paul M. Stein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:27
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; C; C12; C12N; C12N15/00; C12N15/09; C12N15/87; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61F2250/00; A61F2250/0058; A61F2250/0067
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
62 words
An intraluminal stent comprising: a lumen-wall contacting surface; a lumen-exposed surface; a first polymer composition comprising fibrin, the composition covering at least a portion of the lumen-wall contacting surface of the stent; and a virus, comprising nucleic acid, capable of delivering the nucleic acid to a cell wherein the virus is associated with the first polymer composition covering the lumen-wall contacting surface.
Claim 2
Dependent Claim
62 words
An intraluminal stent comprising: a lumen-wall contacting surface; a lumen-exposed surface; a first polymer composition comprising fibrin, the composition covering at least a portion of the lumen-wall contacting surface of the stent; and a virus, comprising nucleic acid, capable of delivering the nucleic acid to a cell wherein the virus is associated with the first polymer composition covering the lumen-wall contacting surface.
Claim 3
Dependent Claim
21 words
The device of claim 1, wherein the first polymer composition includes a polymer or copolymer that is viscoelastic, tear-resistant, and biocompatible.
Claim 4
Dependent Claim
12 words
The device of claim 2, wherein the first polymer composition is nonthrombogenic.
Claim 5
Dependent Claim
16 words
The device of claim 3, wherein the first polymer composition is capable of dehydration and rehydration.
Claim 6
Dependent Claim
27 words
The device of claim 1, wherein the first polymer composition additionally comprises another polymer selected from the group consisting of alginate, collagen, hyaluronic acid, polyurethane and cellulose.
Claim 7
Dependent Claim
11 words
The device of claim 1, wherein the virus is an adenovirus.
Claim 8
Dependent Claim
11 words
The device of claim 1, wherein the virus is a retrovirus.
Claim 9
Dependent Claim
20 words
The device of claim 1, wherein the nucleic acid is capable of directing expression of a protein in a cell.
Claim 10
Dependent Claim
11 words
The device of claim 1, wherein the nucleic acid is RNA.
Claim 11
Dependent Claim
11 words
The device of claim 1, wherein the nucleic acid is DNA.
Claim 12
Dependent Claim
29 words
The device of claim 1, wherein the stent further comprises a second polymer composition covering at least a portion of the first polymer composition on the lumen wall-contacting surface.
Claim 13
Dependent Claim
26 words
The device of claim 11, wherein the stent further comprises a third polymer composition covering at least a part of the lumen-exposed surface of the stent.
Claim 14
Dependent Claim
12 words
The device of claim 11, wherein the second polymer composition is biodegradable.
Claim 15
Dependent Claim
12 words
The device of claim 11, wherein the second polymer composition comprises fibrin.
Claim 16
Dependent Claim
13 words
The device of claim 13, wherein the second polymer composition comprises polylactic acid.
Claim 17
Dependent Claim
15 words
The device of claim 11, wherein the second polymer composition further comprises an anti-inflammatory compound.
Claim 18
Dependent Claim
12 words
The device of claim 16, wherein the anti-inflammatory compound is a cyclosporin.
Claim 19
Dependent Claim
25 words
The device of claim 1, wherein the stent further comprises a polymer composition covering at least a part of the lumen-exposed surface of the stent.
Claim 20
Dependent Claim
22 words
The device of claim 18 wherein the device further comprises a negatively charged polymer composition covering the lumen-exposed surface of the stent.
Claim 21
Dependent Claim
37 words
The device of claim 19 wherein the negatively charged polymer composition is selected from the group consisting of a mucopolysaccharide, dextran-sulfate, an acrylic acid polymer, polyinosinic acid and heparin or a polymer composition comprising a combination thereof.
Claim 22
Independent Claim
110 words
A method for delivering nucleic acid to cells accessible from a wall of a body lumen comprising the steps of: providing a stent comprising a lumen-wall contacting surface, a lumen-exposed surface, a first polymer composition comprising fibrin covering at least a portion of the lumen-wall contacting surface to form a polymer covered stent; and virus comprising nucleic acid associated with the first polymer composition wherein the stent is capable of delivering nucleic acid to cells accessible from a wall of a body lumen; positioning the stent in a lumen of the body; and contacting the lumen-wall contacting surface of the stent with the wall of a lumen of the body.
Claim 23
Independent Claim
110 words
A method for delivering nucleic acid to cells accessible from a wall of a body lumen comprising the steps of: providing a stent comprising a lumen-wall contacting surface, a lumen-exposed surface, a first polymer composition comprising fibrin covering at least a portion of the lumen-wall contacting surface to form a polymer covered stent; and virus comprising nucleic acid associated with the first polymer composition wherein the stent is capable of delivering nucleic acid to cells accessible from a wall of a body lumen; positioning the stent in a lumen of the body; and contacting the lumen-wall contacting surface of the stent with the wall of a lumen of the body.
Claim 24
Dependent Claim
20 words
The method of claim 21, wherein the lumen-wall contacting surface is a portion of a wall of a blood vessel.
Claim 25
Dependent Claim
20 words
The method of claim 21, wherein the lumen-wall contacting surface is a portion of a wall of a lymph vessel.
Claim 26
Dependent Claim
19 words
The method of claim 21, wherein the lumen-wall contacting surface is a portion of a wall of an intestine.
Claim 27
Dependent Claim
20 words
The method of claim 21, wherein the lumen-wall contacting surface is a portion of a wall of a respiratory airway.
Claim 28
Dependent Claim
23 words
The method of claim 21, wherein the positioning step further comprises introducing the stent into a lumen of the body using a catheter.
Claim 29
Dependent Claim
23 words
The method of claim 21, wherein the positioning step further comprises introducing the stent into a lumen of the body by surgical implantation.
Claim 30
Dependent Claim
29 words
The method of claim 21, wherein the method further comprises applying a biodegradable polymer composition to at least a portion of the lumen-wall contacting surface following the loading step.
Claim 31
Dependent Claim
59 words
A kit comprising: a stent comprising a lumen-wall contacting surface, a lumen-exposed surface, and a first polymer composition comprising fibrin covering at least a portion of the lumen-wall contacting surface of the stent; a virus-loading solution to be applied to the stent; and a container to house the stent and the solution during application of the virus loading solution.
Claim 32
Dependent Claim
59 words
A kit comprising: a stent comprising a lumen-wall contacting surface, a lumen-exposed surface, and a first polymer composition comprising fibrin covering at least a portion of the lumen-wall contacting surface of the stent; a virus-loading solution to be applied to the stent; and a container to house the stent and the solution during application of the virus loading solution.
Claim 33
Dependent Claim
8 words
The kit of claim 29, further comprising virus.
References Cited (Backward Citations)
US3523807A
Cited
US4540573A
Cited
US4548736A
Cited
US5102417A
Cited
US4733665A
Cited
US4733665C2
Cited
US4733665B1
Cited
US4800882A
Cited
US4886062A
Cited
EP0366564A2
Cited
US5298255A
Cited
WO1990013332A1
Cited
WO1991012779A1
Cited
WO1992007573A1
Cited
US5372600A
Cited
US5192297A
Cited
US5510077A
Cited
US5449382A
Cited
US5419760A
Cited
US5464650A
Cited
WO1994027612A1
Cited
WO1995003083A1
Cited
US5429634A
Cited
WO1995010623A1
Cited
WO1995014785A1
Cited
WO1995025807A1
Cited
WO1996001902A1
Cited
EP0701801A1
Cited
EP0701802A1
Cited
WO1996011671A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-09 | 2002-05-11 | 2002-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-09 | 2006-05-11 | 2006-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-09 | 2010-05-11 | 2010-11-10 | $7700.00 | Window Closed / Lapsed |